GPR19 and adenocarcinoma: However, due to its high expression rate in adenocarcinomas and neuroendocrine tumours of the lung, including TC, AC, and SCLC, with at the same time only very low occurrence in healthy organs, so that only minor side effects are to be expected, GPR19 clearly represents an interesting diagnostic or therapeutic target that should be investigated further.